之江生物股价跌5%，融通基金旗下1只基金位居十大流通股东，持有150万股浮亏损失217.5万元

Group 1 - The core point of the news is that Zhijiang Bio experienced a 5% drop in stock price, currently trading at 27.53 yuan per share, with a total market capitalization of 5.29 billion yuan [1] - Zhijiang Bio, established on April 18, 2005, and listed on January 18, 2021, specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of Zhijiang Bio includes 82.71% from nucleic acid testing kits, 10.54% from other products, 5.00% from molecular diagnostic instruments, and 1.75% from other sources [1] Group 2 - Among the top circulating shareholders of Zhijiang Bio, a fund under Rongtong Fund has reduced its holdings by 200,000 shares, now holding 1.5 million shares, which represents 0.78% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 2.074 billion yuan and has achieved a year-to-date return of 24.46%, ranking 3000 out of 8194 in its category [2] - The fund has a one-year return of 48.49%, ranking 2565 out of 7962, and a cumulative return since inception of 200.7% [2] Group 3 - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 3 days [3] - The total asset scale of the fund is 4.223 billion yuan, with the best return during Wan's tenure being 163.77% and the worst being -14.89% [3]